Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

Agenus (NASDAQ: AGEN), a leader in immuno-oncology, will participate in the 5th Annual Evercore ISI HealthCONx Conference. Dr. Garo Armen and Dr. Steven O'Day will join a virtual fireside chat on November 30th at 12:35 PM ET. The conference runs from November 29th to December 1st, including one-on-one investor meetings. Interested attendees can register for the webcast, which will also be archived on Agenus' investor website following the event. Agenus focuses on therapies that harness the immune system to combat cancer and infections.

News Market Reaction – AGEN

+2.52%

+2.52% Session move

In the trading session that priced this news, AGEN gained 2.52%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a virtual fireside chat at the 5^th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 12:35pm ET. The Conference will be held virtually from November 29th – December 1st, during which Agenus will host one-on-one meetings with investors.

Registration for the webcast can be accessed at https://wsw.com/webcast/evercore29/agen/2333250. Following the webcast, an archived version will be available on the Investors section of the Agenus website at https://investor.agenusbio.com/events-and-presentations.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Inc.
Nico Frelick
Investor Relations
781-674-4616
Nico.frelick@agenusbio.com

 

FAQ

When will Agenus participate in the Evercore ISI HealthCONx Conference?

Agenus will participate in the 5th Annual Evercore ISI HealthCONx Conference on November 30th at 12:35 PM ET.

Who from Agenus will speak at the conference?

Dr. Garo Armen, Chairman and CEO, and Dr. Steven O'Day, Chief Medical Officer, will speak at the conference.

What is the duration of the Evercore ISI HealthCONx Conference?

The conference will be held virtually from November 29th to December 1st.

How can I register for the Agenus webcast at the conference?

You can register for the webcast through the link provided in the press release or on Agenus' investor website.

Will the Agenus conference presentation be available after the event?

Yes, an archived version of the presentation will be available on the Investors section of the Agenus website after the event.